Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 7, 2006

SRI International Recipient of $56.9M from the NIAID

  • SRI International has been awarded a $56.9-million contract from the NIAID to provide preclinical services for the development of drugs and antibodies for anti-infective therapeutics.

    SRI will support the development of treatments for avian flu, SARS, West Nile virus, hepatitis, and biodefense pathogens and toxins for five years. The company will perform medicinal chemistry, custom drug synthesis, formulation, analytical chemistry, clinical manufacturing, microbiology and virology screening, pharmacokinetics, safety testing, and preparation of IND applications to the FDA.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »